Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (OTCQB: PPCB) announced new research published in Expert Opinion on Biological Therapy, confirming the anti-tumor efficacy of pancreatic proenzymes, trypsinogen and chymotrypsinogen. The study shows these proenzymes can sensitize cancer stem cells (CSCs), enhancing the effectiveness of standard treatments like chemotherapy. Key findings include reduced CSC proliferation and migration, induction of cell differentiation, impaired angiogenesis, and decreased metastatic potential. The research supports proenzymes as a potential adjuvant therapy for late-stage cancer patients.
Propanc Biopharma, Inc. (OTCQB: PPCB) provided a shareholder update, highlighting confidence in a post-pandemic recovery. With improved economic conditions, the company is focusing on capital restructuring and advancing its lead product, PRP, towards a Phase I clinical study. The update emphasizes significant progress in scientific research, particularly in proenzyme therapy, and anticipates cash-back benefits from the Australian government for R&D. Strong institutional support is noted, alongside new therapeutic discoveries aimed at combating aggressive cancer types.
Propanc Biopharma, Inc. (OTCQB: PPCB) has reported promising results from its Proenzymes Optimization Project 1 (POP1), which indicates that pancreatic proenzymes may inhibit cancer spread and improve outcomes for patients with metastatic cancers. Professor Juan Marchal, a key advisor, predicts that these findings could lead to effective new treatments. The company is looking to initiate Phase II clinical studies in Spain for pancreatic and ovarian cancers after completing Phase I trials in Australia. Propanc aims to develop a superior clinical compound for commercial use while partnering with leading universities.
Propanc Biopharma, Inc. (OTCQB: PPCB) announced the appointment of Ms. Belen Toledo MSc., a biotechnologist, to lead research on the impact of proenzyme therapy on the tumor microenvironment as part of the Proenzymes Optimization Project 1 (POP1). The project aims to produce commercial quantities of trypsinogen and chymotrypsinogen without animal sourcing. The research, conducted with the University of Granada, utilizes 3D tumor models to assess proenzyme therapy's effects on cancer cells while sparing healthy cells, enhancing prospects for effective cancer treatments.
Propanc Biopharma (OTC: PPCB) has received expressions of interest from oncologists at the University Hospital of Jaén to evaluate its proenzyme therapy for preventing recurrence and metastasis in pancreatic and ovarian cancers. This evaluation will likely lead to Phase IIa proof of concept studies for each indication, following a planned Phase Ib study in 2021 at the Peter Mac Cancer Center. The company aims to conduct trials in Europe due to the larger patient population, indicating a strategic move to enhance its clinical research footprint.
Propanc Biopharma (OTC: PPCB) is on a mission to revolutionize cancer treatment by analyzing the efficacy of pancreatic proenzymes versus T-Cell therapy for solid tumors like pancreatic, ovarian, and colorectal cancers. Led by CEO James Nathanielsz and researcher Professor Macarena Perán, the company aims to enhance patient survival and reduce treatment toxicity. Their novel cell differentiation therapy targets cancer stem cells, potentially offering a safer, more effective solution compared to traditional therapies, while the eye-watering costs of T-Cell therapies remain a concern.
Propanc Biopharma, Inc. (OTC: PPCB) has advanced its Proenzymes Optimization Project 1 (POP1) aimed at producing large quantities of proenzymes trypsinogen and chymotrypsinogen for cancer treatment. The global metastatic cancer treatment market is expected to reach US$111.2 billion by 2027. Lead researcher Aitor González has successfully synthesized and purified these proenzymes, which will be further scaled at the MEDINA Foundation. CEO James Nathanielsz emphasized the goal to create less toxic cancer treatment options, while Dr. Julian Kenyon highlighted progress in developing synthetic versions.
Propanc Biopharma (OTC: PPCB) announced the grant of a significant patent from the Australian Patent Office, marking a pivotal moment in its intellectual property strategy. This patent covers methods for utilizing pancreatic proenzymes to target and eliminate cancer stem cells (CSCs), which are responsible for cancer recurrence and metastasis. The lead product candidate, PRP, aims to improve treatments for patients with advanced solid tumors by reducing CSCs while preserving normal stem cells. The company holds a total of 65 patents across four families, emphasizing its commitment to innovation in cancer therapy.